Journal
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Volume 216, Issue -, Pages 59-62Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autneu.2018.09.005
Keywords
Parkinson's disease; Autonomic; Striatal; Dopamine transporter; DAT
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research
- AbbVie
- Avid
- Biogen
- Bristol-Myers Squibb
- Covance
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lundbeck
- Eli Lilly
- Merck
- Meso Scale Discovery
- Pfizer
- Piramal
- Roche
- Sanofi Genzyme
- Servier
- TEVA
- UCB
Ask authors/readers for more resources
While the involvement of the central and peripheral autonomic networks is thought to play an integral role in the development of autonomic symptoms in Parkinson's disease (PD), there is little evidence for an association between autonomic symptoms and striatal dopaminergic depletion. We compared dopamine transporter activity in striatal subregions with various autonomic symptoms covered by the SCOPA-AUT domains including gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual symptoms in 418 untreated patients with PD. We found evidence for a dopaminergic association with only urinary symptoms. Moreover, dopaminergic denervation in the putamen but not in the caudate may underlie these symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available